TANAFFOS (Respiration)

TANAFFOS (Respiration)

Caspofungin as Salvage Therapy for Pneumocystis Pneumonia in a Heart Transplant Recipient

Authors
Sara Abolghasemi 1
Babak Sharif-Kashani 2
Farah Naghashzadeh 2
Majid Marjani 3
Afshin Monir 4
Atousa Doroudinia 4
Payam Tabarsi 4
1 1Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Chronic Respiratory Disease Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 1Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4 Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Pneumocystis pneumonia (PCP) is a common opportunistic infection in immunocompromised patients. In general, clinical response to therapy with cotrimoxazole is excellent. However, therapy may be limited by side effects or treatment failure. We present a case of PCP in a 35-year-old male patient with history of heart transplantation and renal failure who was admitted with a 10- day history of fever, nonproductive cough and elevated level of creatinine with a diagnosis of PCP confirmed by chest radiography and in bronchoalveolar lavage specimens. He was treated with trimethoprim-sulphamethoxazole (SMZ/TMP) and primaquine but treatment was completed with reduced dosage of cotrimoxazole, primaquine and with the addition of caspofungin. This therapy was effective and without any adverse effects in a patient with elevated level of creatinine
Keywords
Pneumocystis Pneumonia
Chronic renal failure
Caspofungin
TANAFFOS (Respiration)
Volume 17, Issue 3 - Serial Number 3
Autumn 2018
Pages 203-206